UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
12b-25
NOTIFICATION
OF LATE FILING
|
(Check
One):
|
o
Form 10-K and
Form 10-KSB
|
o
Form 20-F
|
o
Form 11-K
|
|
x
Form 10-Q and
Form 10-QSB
|
o
Form N-SAR
|
For
Period Ended: May 31, 2008
|
o
Transition Report on Form 10-K
|
o
Transition Report on Form 10-Q
|
|
o
Transition Report on Form 20-F
|
o
Transition Report on Form N-SAR
|
|
o
Transition Report on Form 11-K
|
For
the
Transition Period Ended :________________________
Read
attached instruction sheet before preparing form. Please print or
type.
Nothing
in this form shall be construed to imply that the Commission has verified
any
information contained herein.
If
the
notification related to a portion of the filing checked above, identify the
item(s) to which the notification relates:
PART
I
REGISTRANT
INFORMATION
Full
name
of registrant: Oramed Pharmaceuticals
Inc.
Former
name if applicable: Integrated Security Technologies, Inc.
Address
of principal executive office (street and number): Hi-Tech Park 2/5 Givat
Ram,
PO Box 39098
City,
state and zip code: Jerusalem, Israel 91390
PART
II
RULE
12b-25 (b) and (c)
If
the
subject report could not be filed without unreasonable effort or expense
and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should
be
completed. (Check box if appropriate.)
|
x
|
(a)
|
The
reasons described in reasonable detail in Part III of this form
could not
be eliminated without unreasonable effort or expense.
|
|
x
|
(b)
|
The
subject annual report, semi-annual report, transition report
on Form 10-K,
20-F, 11-K, Form N-SAR or Form N-CSR, or portion thereof will
be filed on
or before the fifteenth calendar day following the prescribed
due date; or
the subject quarterly report or transition report on Form 10-Q
or portion
thereof will be filed on or before the fifth calendar day following
the
prescribed due date; and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
PART
III
NARRATIVE
State
below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR
or
the transition report portion thereof could not be filed within the prescribed
time period.
Oramed
Pharmaceuticals Inc. (the “Registrant”) is unable to file its Quarterly Report
on Form 10QSB for the quarter ended May 31, 2008 (the “Form 10QSB”) by the
initial filing deadline of July 15, 2008 without unreasonable effort and
expense
because the Registrant has encountered a delay in assembling the information,
in
particular its financial statements for the quarter ended May 31, 2008, required
to be included in its May 31, 2008 Form 10QSB. The Registrant intends to
have
the Form 10QSB filed as soon as practicable, and in no event later than the
fifth calendar day following the prescribed due date.
PART
IV
OTHER
INFORMATION
|
(1)
|
Name
and telephone number of person to contact in regard to this notification:
Nadav Kidron, Chief Executive Officer at
972-2-566-0001.
|
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of
the
Securities Exchange Act of 1934 or Section 30 of the Investment
Company
Act of 1940 during the preceding 12 months or for such shorter
period that
the registrant was required to file such report(s) been filed?
If the
answer is no, identify report(s)
|
x
Yes o No
2
|
(3)
|
Is
it anticipated that any significant change in results of operations
from
the corresponding period for the last fiscal year will be reflected
by the
earnings statements to be included in the subject report or portion
thereof?
|
o
Yes x No
If
so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reason why a reasonable estimate
of the results cannot be made.
Oramed
Pharmaceuticals Inc.
(Name
of
Registrant as specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned thereunto
duly authorized.
| Date: July 16, 2007 | By: | /s/ Nadav Kidron |
|
Nadav Kidron |
||
| Chief Executive Officer | ||
3